Polydeoxyribonucleotide Treatment in Genital Lichen Sclerosus in Males.

It has been reported that treatment with polydeoxyribonucleotide (PDRN) in males affected by lichen sclerosus significantly improves the overall conditions of treated patients. It confirms that PDRN has a potent cytoprotective action as in other pathological conditions. We believe that multicentric randomized clinical trials are necessary for testing the benefits of this promising agent.